Drug Profile
LY 333068
Latest Information Update: 22 Aug 2001
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anxiolytics; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
- Mechanism of Action 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Smoking withdrawal
Most Recent Events
- 22 Aug 2001 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 22 Aug 2001 No-Development-Reported for Smoking withdrawal in USA (Unknown route)
- 03 Apr 1998 Preclinical development for Smoking withdrawal in USA (Unknown route)